Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KSE · KRW · Healthcare · Drug Manufacturers - Specialty & Generic
₩19,310 (+0.78%) as of
Key statistics
- Market cap
- 244.42B
- Forward P/E
- 10.38
- Dividend yield
- 4.18%
- 52-week range
- 16,580.00 – 25,900.00
- Beta
- 0.22
- Revenue (TTM)
- 274.03B
- Profit margin
- 7.99%
- Analyst target
- ₩26,000
- Volume
- 36.56k
About Samjin Pharmaceuticals Co., Ltd.
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Seoul, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.